LIVC Technologies GmbH
About LIVC Technologies
LIVC Technologies GmbH, based in Frankfurt am Main, Germany, specializes in the screening of voltage-gated ion channels using Light Induced Voltage Clamp (LIVC). This technology enables high-throughput screening of voltage-gated ion channels for the first time without loss of time or information. The company focuses on the development and commercialization of assay technologies.
LIVC Technologies was founded in November 2006 and works in close cooperation with the Max Planck Institute for Biophysics. The founders come from academic research, biotechnology and venture capital backgrounds. In addition to the founders, IonGate Biosciences GmbH, Frankfurt, is a shareholder.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Laboratory analysis / Laboratory measurement technology
Here you will find LIVC Technologies GmbH
Last viewed contents
Global Network for Neglected Tropical Diseases - Washington, USA
FVG-Filter Vertriebs GmbH - Idstein, Germany
Hyperthermia
Clavis Pharma Announces Recruitment of Patients in Phase II Study comparing CP-4126 with gemcitabine in pancreatic cancer
Isotretinoin
Genmab's Humax-CD20 cancer antibody shows promising results in primate study - HuMax-CD20 depleted B-cells, the target in non-Hodgkins lymphoma, for longer than rituximab
Dimethaid announces new pancreatic cancer trial with WF10 - Phase II trial to be initiated at University of Heidelberg
Limitations of Chemotherapy Regimes Coupled with Increasing Incidence of Cancer is Driving Uptake of Cancer Support Therapies
Biontex Laboratories GmbH - Martinsried, Germany
CyGenics Granted Key Patent for the China Market
Heptares scientists report the first use of structure-based drug design to discover GPCR-targeted drug candidate
